Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/08/020680
CTRI/2019/08/020680
Completed
Phase 3

Phase-III Clinical Trial with an Intravasal Injectable Male Contraceptive â?? RISUG® - RISUG

Indian Council of Medical Research0 sites303 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Indian Council of Medical Research
Enrollment
303
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
July 22, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Age at the time of induction to be in the range 25 \- 40 years
  • •2\. Have two or more normal healthy living children
  • •3\. Be in good health
  • •4\. Normal reproductive system and semen parameters (determined by clinical examination and laboratory investigations)
  • •5\. Wife healthy
  • •6\. Wife not pregnant at the time of induction of the male into the programme (pregnancy to be excluded by menstrual history, clinical examination and if necessary pregnancy test)
  • •7\. Wife has not undergone sterilization operation
  • •8\. In case wife has an intrauterine device she should agree to removal of the IUD when the male partner is inducted into the programme.
  • •9\. The couple should agree to avoid the use of any contraceptives other than what is advised during the study and in case of conception they should be prepared to undergo Medical Termination of Pregnancy.
  • •10\. Couple willing to follow the follow up schedule and will undergo all the clinical and laboratory examinations

Exclusion Criteria

  • •1\. Sexually transmitted disease in either partner
  • •2\. Impotence
  • •3\. Any psychiatric disorders like anxiety problem
  • •4\. Chronic pelvic infection or cervical carcinoma of wife
  • •5\. Diabetes Mellitus
  • •6\. Any pathology including diseases, which may interfere with the action of the contraceptive agent, induce complications or introduce variables, which may bring in ambiguities in the interpretation of the observations. For example azoospermia or oligozoospermia, cryptorchidism, testicular atrophy, testicular tumors, epididymo\-orchitis, cysts and spermatocele related to the epididymis, varicocele, palpably hypertrophied vas deferens, any indications of tuberculosis of the vas deferens etc.
  • •7\. Pre\-existing vaginitis, cervicitis and cervical dysplasia may be wrongly attributed to such an implantation of the polymer into the female system. Vaginitis, cervicitis and cervical dysplasia are to be treated but those with cervical carcinoma in situ and advanced grades of carcinoma are to be excluded.
  • •8\. The male partners of the women having tuberculosis of the reproductive organs, fibroid and other gynecological problems, which may later affect the pregnancy, also have to be eliminated.
  • •9\. Wife is not willing to undergo periodic pregnancy test if advised.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 1
Mesenchymal Stem Cell Therapy For Covid 19Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
CTRI/2020/08/027043eurogen Brain and Spine Institute
Completed
Not Applicable
A randomised phase III study of intravenous (i.v.) zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myelomaMultiple myelomaCancerMultiple myeloma and malignant plasma cell neoplasms
ISRCTN23172547Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)407
Completed
Phase 3
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC).hepatocellular carcinomaliver cancer10019815
NL-OMON50334Biocompatibles UK Ltd.38
Completed
Phase 1
A clinical trial of intra-arterial infusion chemotherapy with cisplatin for head and neck cancerHead and neck squamous cell carcinoma
JPRN-UMIN000017656Department of Radiology Mie University Graduate School of Medicine18
Not yet recruiting
Phase 2
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis (TCIM-ELAII)
2023-506215-17-00Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia100